Affirmed Therapeutics BV (AFMD) Receives $10.75 Average Price Target from Brokerages
Shares of Affirmed Therapeutics BV (NASDAQ:AFMD) have been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the stock. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $10.75.
Several analysts have recently commented on the company. Zacks Investment Research upgraded Affirmed Therapeutics BV from a “sell” rating to a “hold” rating in a report on Monday, November 7th. Leerink Swann reiterated a “hold” rating and issued a $2.00 price target on shares of Affirmed Therapeutics BV in a report on Thursday, November 3rd. Finally, Jefferies Group reiterated a “hold” rating on shares of Affirmed Therapeutics BV in a report on Tuesday, August 9th.
Institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its position in Affirmed Therapeutics BV by 237.2% in the first quarter. Wellington Management Group LLP now owns 3,561,141 shares of the biopharmaceutical company’s stock valued at $13,318,000 after buying an additional 2,505,031 shares during the last quarter. Perceptive Advisors LLC bought a new position in Affirmed Therapeutics BV during the second quarter valued at $1,821,000. Opaleye Management Inc. raised its position in Affirmed Therapeutics BV by 2.5% in the first quarter. Opaleye Management Inc. now owns 610,000 shares of the biopharmaceutical company’s stock valued at $2,281,000 after buying an additional 15,000 shares during the last quarter. Baker BROS. Advisors LP bought a new position in Affirmed Therapeutics BV during the third quarter valued at $1,112,000. Finally, Lombard Odier Asset Management USA Corp raised its position in Affirmed Therapeutics BV by 4.7% in the second quarter. Lombard Odier Asset Management USA Corp now owns 365,677 shares of the biopharmaceutical company’s stock valued at $907,000 after buying an additional 16,555 shares during the last quarter. 43.03% of the stock is currently owned by hedge funds and other institutional investors.
Affirmed Therapeutics BV (NASDAQ:AFMD) opened at 2.30 on Monday. Affirmed Therapeutics BV has a 1-year low of $1.75 and a 1-year high of $8.26. The stock’s market cap is $77.02 million. The firm’s 50-day moving average price is $2.31 and its 200 day moving average price is $2.84.
Affirmed Therapeutics BV (NASDAQ:AFMD) last announced its earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.05. The business had revenue of $0.94 million for the quarter, compared to the consensus estimate of $2.65 million. Affirmed Therapeutics BV had a negative return on equity of 57.35% and a negative net margin of 501.31%. Affirmed Therapeutics BV’s revenue for the quarter was down 18.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.24) EPS. Equities research analysts expect that Affirmed Therapeutics BV will post ($1.18) EPS for the current year.
About Affirmed Therapeutics BV
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Stock Ratings for Affirmed Therapeutics BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affirmed Therapeutics BV and related stocks with our FREE daily email newsletter.